Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
General issues related to health care and pharmaceuticals; drug pricing; patent reform; Medicare issues, including drug price negotiations; FDA issues; FTC issues; H.R.8267 - Old Drugs, New Cures Act
General issues related to health care and pharmaceuticals; drug pricing; patent reform; Medicare issues, including drug price negotiations; FDA issues; FTC issues; H.R.8267 - Old Drugs, New Cures Act
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
BAUSCH HEALTH COMPANIES via BAUSCH HEALTH COMPANIES
2026 · first_quarter · 1T
General issues related to health care and pharmaceuticals; drug pricing; patent reform; Medicare issues, including drug price negotiations; FDA issues; FTC issues; H.R.8267 - Old Drugs, New Cures Act
Filing targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAUSCH HEALTH COMPANIES via BAUSCH HEALTH COMPANIES
2025 · fourth_quarter · Q4
Source: Senate LDA
General issues related to health care and pharmaceuticals; drug pricing; patent reform; Medicare issues, including drug price negotiations; FDA issues; FTC issues; H.R.8267 - Old Drugs, New Cures Act
General issues related to health care and pharmaceuticals; drug pricing; patent reform; Medicare issues, including drug price negotiations; FDA issues; FTC issues; H.R.8267 - Old Drugs, New Cures Act
General issues related to health care and pharmaceuticals; drug pricing; patent reform; Medicare issues, including drug price negotiations; FDA issues; FTC issues; H.R.8267 - Old Drugs, New Cures Act
General issues related to health care and pharmaceuticals; drug pricing; patent reform; eye health issues; Medicare issues; FDA issues; FTC issues; H.R.8267 - Old Drugs, New Cures Act
General issues related to health care and pharmaceuticals; drug pricing; patent reform; eye health issues; Medicare issues, including drug price negotiations; FDA issues; FTC issues; H.R.8267 - Old Drugs, New Cures Act
General issues related to health care and pharmaceuticals; drug pricing; patent reform; Medicare issues, including drug price negotiations; FDA issues; FTC issues; H.R.8267 - Old Drugs, New Cures Act
Filing targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAUSCH HEALTH COMPANIES via BAUSCH HEALTH COMPANIES
2025 · third_quarter · Q3
General issues related to health care and pharmaceuticals; drug pricing; patent reform; Medicare issues, including drug price negotiations; FDA issues; FTC issues; H.R.8267 - Old Drugs, New Cures Act
Filing targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAUSCH HEALTH COMPANIES via BAUSCH HEALTH COMPANIES
2025 · second_quarter · Q2
General issues related to health care and pharmaceuticals; drug pricing; patent reform; Medicare issues, including drug price negotiations; FDA issues; FTC issues; H.R.8267 - Old Drugs, New Cures Act
Filing targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAUSCH HEALTH COMPANIES via BAUSCH HEALTH COMPANIES
2025 · first_quarter · Q1
General issues related to health care and pharmaceuticals; drug pricing; patent reform; Medicare issues, including drug price negotiations; FDA issues; FTC issues; H.R.8267 - Old Drugs, New Cures Act
Filing targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAUSCH HEALTH COMPANIES via BAUSCH HEALTH COMPANIES
2024 · fourth_quarter · Q4
General issues related to health care and pharmaceuticals; drug pricing; patent reform; eye health issues; Medicare issues, including drug price negotiations; FDA issues; FTC issues; H.R.8267 - Old Drugs, New Cures Act
Filing targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAUSCH HEALTH COMPANIES via BAUSCH HEALTH COMPANIES
2024 · third_quarter · Q3
General issues related to health care and pharmaceuticals; drug pricing; patent reform; eye health issues; Medicare issues; FDA issues; FTC issues; H.R.8267 - Old Drugs, New Cures Act
Filing targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAUSCH HEALTH COMPANIES via BAUSCH HEALTH COMPANIES
2024 · second_quarter · Q2
General issues related to health care and pharmaceuticals; drug pricing; patent reform; eye health issues; Medicare issues; FDA issues; FTC issues
Filing targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAUSCH HEALTH COMPANIES via BAUSCH HEALTH COMPANIES
2024 · first_quarter · Q1
General issues related to health care and pharmaceuticals; drug pricing; patent reform; eye health issues; Medicare issues; FDA issues; FTC issues
Filing targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAUSCH HEALTH COMPANIES via BAUSCH HEALTH COMPANIES
2023 · fourth_quarter · Q4
General issues related to health care and pharmaceuticals; drug pricing; patent reform; eye health issues; Medicare issues; FDA issues; FTC issues
Filing targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAUSCH HEALTH COMPANIES via BAUSCH HEALTH COMPANIES
2023 · third_quarter · Q3
General issues related to health care and pharmaceuticals; drug pricing; patent reform; eye health issues; Medicare issues; FDA issues; FTC issues
Filing targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAUSCH HEALTH COMPANIES via BAUSCH HEALTH COMPANIES
2023 · second_quarter · Q2
General issues related to health care and pharmaceuticals; drug pricing; patent reform; eye health issues; Medicare issues; FDA issues; FTC issues
Filing targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAUSCH HEALTH COMPANIES via BAUSCH HEALTH COMPANIES
2023 · first_quarter · Q1
General issues related to health care and pharmaceuticals; drug pricing; patent reform; eye health issues; Medicare issues; FDA issues; FTC issues
Filing targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAUSCH HEALTH COMPANIES via BAUSCH HEALTH COMPANIES
2022 · fourth_quarter · Q4
General issues related to health care and pharmaceuticals; drug pricing; patent reform; eye health issues; Medicare issues; FDA issues; FTC issues
Filing targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAUSCH HEALTH COMPANIES via BAUSCH HEALTH COMPANIES
2022 · third_quarter · Q3
General issues related to health care and pharmaceuticals; drug pricing; patent reform; eye health issues; Medicare issues; FDA issues; FTC issues
Filing targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAUSCH HEALTH COMPANIES via BAUSCH HEALTH COMPANIES
2022 · second_quarter · Q2
General issues related to health care and pharmaceuticals; drug pricing; patent reform; eye health issues; Medicare issues; FDA issues; FTC issues
Filing targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAUSCH HEALTH COMPANIES via BAUSCH HEALTH COMPANIES
2022 · first_quarter · Q1
General issues related to health care and pharmaceuticals; drug pricing; patent reform; eye health issues; Medicare issues; FDA issues; FTC issues
Filing targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAUSCH HEALTH COMPANIES via BAUSCH HEALTH COMPANIES
2021 · fourth_quarter · Q4
General issues related to health care and pharmaceuticals; drug pricing; patent reform; eye health issues; Medicare issues; FDA issues; FTC issues
Filing targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAUSCH HEALTH COMPANIES via BAUSCH HEALTH COMPANIES
2021 · third_quarter · Q3
General issues related to health care and pharmaceuticals; drug pricing; patent reform; eye health issues; Medicare issues; FDA issues; FTC issues
Filing targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAUSCH HEALTH COMPANIES via BAUSCH HEALTH COMPANIES
2021 · second_quarter · Q2
General issues related to health care and pharmaceuticals; drug pricing; patent reform; eye health issues; Medicare issues; FDA issues; FTC issues
Filing targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAUSCH HEALTH COMPANIES via BAUSCH HEALTH COMPANIES
2021 · first_quarter · Q1
General issues related to health care and pharmaceuticals; drug pricing; patent reform; eye health issues; Medicare issues; FDA issues; FTC issues
Filing targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAUSCH HEALTH COMPANIES via BAUSCH HEALTH COMPANIES
2020 · fourth_quarter · Q4
General issues related to health care and pharmaceuticals; drug pricing; patent reform; eye health issues; Medicare issues; FDA issues; FTC issues
Filing targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAUSCH HEALTH COMPANIES via BAUSCH HEALTH COMPANIES
2020 · third_quarter · Q3
General issues related to health care and pharmaceuticals; drug pricing; patent reform; eye health issues; Medicare issues; FDA issues; FTC issues
Filing targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAUSCH HEALTH COMPANIES via BAUSCH HEALTH COMPANIES
2020 · second_quarter · Q2
General issues related to health care and pharmaceuticals; drug pricing; patent reform; eye health issues; Medicare issues; FDA issues; FTC issues
Filing targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAUSCH HEALTH COMPANIES via BAUSCH HEALTH COMPANIES
2020 · first_quarter · Q1
General issues related to health care and pharmaceuticals; drug pricing; patent reform; eye health issues; Medicare issues; FDA issues.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAUSCH HEALTH COMPANIES via BAUSCH HEALTH COMPANIES
2019 · fourth_quarter · Q4
General issues related to health care and pharmaceuticals; issues related to opioids and opioid withdrawal syndrome; drug pricing; patent reform; eye health issues.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAUSCH HEALTH COMPANIES via BAUSCH HEALTH COMPANIES
2019 · third_quarter · Q3
General issues related to health care and pharmaceuticals; issues related to opioids and opioid withdrawal syndrome; drug pricing; patent reform; eye health issues.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAUSCH HEALTH COMPANIES via BAUSCH HEALTH COMPANIES
2019 · second_quarter · Q2
General issues related to health care and pharmaceuticals; issues related to opioids and opioid withdrawal syndrome; drug pricing; patent reform; eye health issues.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAUSCH HEALTH COMPANIES via BAUSCH HEALTH COMPANIES
2019 · first_quarter · Q1
General issues related to health care and pharmaceuticals; issues related to opioids and opioid withdrawal syndrome.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAUSCH HEALTH COMPANIES via BAUSCH HEALTH COMPANIES
2018 · fourth_quarter · Q4
General issues related to health care and pharmaceuticals; issues related to opioids
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BAUSCH HEALTH COMPANIES via BAUSCH HEALTH COMPANIES
2018 · third_quarter · Q3
General issues related to health care and pharmaceuticals
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BAUSCH HEALTH COMPANIES via BAUSCH HEALTH COMPANIES
2018 · third_quarter · RA
General issues related to health care and pharmaceuticals.
BAUSCH HEALTH COMPANIES via BAUSCH HEALTH COMPANIES
2018 · third_quarter · RR
General issues related to health care and pharmaceuticals.